Benefits and Harms of CT Screening for Lung Cancer

Abstract

Bach reported that he has received speaking fees from Genentech. Dr. Detterbeck reported that he was reimbursed for travel costs associated with his work on the Oncimmune advisory board, and has participated without compensation in a symposium on CT screening sponsored by Covidien. Dr.Berry reported that he is co-owner of Berry Consultants LLC which designs adaptive clinical trials for pharmaceutical companies, medical device companies and NIH cooperative groups. To the best of his knowledge none of these parties have any interest in lung cancer screening. Dr. Gould reported that he receives grant support from the National Cancer Institute. Dr. Jett reported that he has grants pending for work related to screening and early detection of lung cancer with Oncimmune and Isense. Dr. Sabichi reported her membership on the National Cancer Institute's PDQ Prevention and Screening Editorial Board and her possession of a pending patent for a test for the detection of bladder cancer. Dr. Wood reported his participation in the development of the National Comprehensive Cancer Network's clinical practice guidelines for lung cancer screening in his role as Chair of the NCCN Lung Cancer Screening Panel.

VSIG4 expression on macrophages facilitates lung cancer development

“…Patients with this carcinoma derive only limited benefits from standard surgical treatments, radiotherapy, chemotherapy, or adjuvant hormone therapies, and the 5-year survival rate after diagnosis remains lower than 15%. 1 Recently, multiple novel therapeutic strategies have been proposed. Most notably, approaches that aim to recruit the host's immune system to identify and destroy aberrant tumor cells have acquired considerable attention.…”

The Inconclusive Evidence on CT Screening for Lung Cancer

“…The American College of Chest Physicians, the American Society of Clinical Oncology [31], and the American Lung Association [32], now recommend screening for persons who meet NLST eligibility criteria. The National Comprehensive Cancer Network [33] and the American Association of Thoracic Surgeons (AATS) [34] made a broader recommendation to include those as young as 50 and those who have as few as 20 pack-years of smoking, if they have other risk factors such as asbestos exposure, chronic obstructive pulmonary disease, or a family history of lung cancer.…”

Public views on participating in newborn screening using genome sequencing

“…It is possible that the sensationalized rhetoric around science and genomics has promulgated both enthusiasm and healthy scepticism of its limits and applications for health care and screening. It is also possible that the heightened discourse emerging about the potential harms of cancer screening 38,39 has moderated the enthusiasm towards screening generally. Indeed, those who understood the varied effects of NBS were less willing, and felt less of a parental responsibility, to participate in NBS using new genomic technologies.…”